SRPT as reported
Sarepta Therapeutics, Inc. reported $2.18B of revenue over the trailing twelve months, −2.2% on the year before. 10 reported series are charted on this page, each one as filed.
$2.18B
Revenue, trailing twelve months · to Q1 2026 · −2.2% against the twelve months before
- Net Income
- $65M
Net Income · −126% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $115M
Free Cash Flow · −117% year on year · trailing twelve months to Q1 2026
- Op Margin
- −13%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $2.18B | −2.2% | Q1 2026 |
| Net Income | $65M | −126% | Q1 2026 |
| EPS | $0.34 | −113% | Q1 2026 |
| Gross Margin | 43% | n/a | Q4 2025 |
| Op Margin | −13% | n/a | Q1 2026 |
| Net Margin | −7.1% | n/a | Q1 2026 |
| ROE | −18% | n/a | Q1 2026 |
| ROA | −6.2% | n/a | Q1 2026 |
| ROIC | 3.1% | n/a | Q4 2024 · 5 quarters behind |
| Free Cash Flow | $115M | −117% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Sarepta Therapeutics, Inc. (SRPT) - Revenue & ProfitRevenue & ProfitSarepta Therapeutics, Inc. (SRPT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com